Efficacy of topical cyclosporine A in optimizing ocular surface and relieving dry eye symptoms after cataract surgery: a systematic review and meta-analysis of randomized controlled trials.
{"title":"Efficacy of topical cyclosporine A in optimizing ocular surface and relieving dry eye symptoms after cataract surgery: a systematic review and meta-analysis of randomized controlled trials.","authors":"Min Lu, Huaifeng Li, Xiang Xiang","doi":"10.1007/s10792-025-03570-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Dry eye symptoms and signs are common following cataract surgery. Topical cyclosporine A (CsA) is an approved treatment of moderate-to-severe dry eye disease. However, its effectiveness in managing postoperative dry eye remains debated. This systematic review and meta-analysis aimed to evaluate the efficacy of topical CsA in managing dry eye symptoms and signs after cataract surgery.</p><p><strong>Methods: </strong>Randomized controlled trials (RCTs) assessing topical CsA in cataract surgery patients were identified through searches of PubMed, EMBASE, Web of Science, ClinicalTrials.gov, the Cochrane Library, and Google Scholar up to August 31, 2024. Outcomes included postoperative tear break-up time (TBUT), Schirmer's test (with or without anesthesia), the Ocular Surface Disease Index (OSDI), corneal fluorescein staining, and treatment-related adverse events.</p><p><strong>Results: </strong>Nine RCTs involving 451 patients (558 eyes) were included. Topical CsA was significantly associated with prolonged TBUT (mean difference [MD] = 1.95 s, 95% confidence interval [CI]: 1.38 to 2.53, P < 0.001), improved Schirmer's test scores without anesthesia (MD = 2.14 mm, 95%CI: 0.68 to 3.59, P = 0.004), and reduced corneal fluorescein staining (standardized MD = - 1.62, 95%CI: - 3.16 to - 0.08, P = 0.039). However, CsA did not significantly improve Schirmer's test scores with anesthesia (MD = 1.73 mm, 95%CI: - 0.11 to 3.56 to 2.79, P = 0.066) or OSDI scores (MD = - 2.73, 95%CI: - 7.42 to 1.97, P = 0.255) compared to control. All treatment-related adverse events were mild.</p><p><strong>Conclusion: </strong>Topical CsA significantly improves ocular surface and tear film parameters following cataract surgery and may be considered for the postoperative management of ocular surface disturbance and dry eye. However, considering the very low to moderate certainty of evidence, further high-quality RCTs are needed to validate for these findings.</p>","PeriodicalId":14473,"journal":{"name":"International Ophthalmology","volume":"45 1","pages":"201"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10792-025-03570-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Dry eye symptoms and signs are common following cataract surgery. Topical cyclosporine A (CsA) is an approved treatment of moderate-to-severe dry eye disease. However, its effectiveness in managing postoperative dry eye remains debated. This systematic review and meta-analysis aimed to evaluate the efficacy of topical CsA in managing dry eye symptoms and signs after cataract surgery.
Methods: Randomized controlled trials (RCTs) assessing topical CsA in cataract surgery patients were identified through searches of PubMed, EMBASE, Web of Science, ClinicalTrials.gov, the Cochrane Library, and Google Scholar up to August 31, 2024. Outcomes included postoperative tear break-up time (TBUT), Schirmer's test (with or without anesthesia), the Ocular Surface Disease Index (OSDI), corneal fluorescein staining, and treatment-related adverse events.
Results: Nine RCTs involving 451 patients (558 eyes) were included. Topical CsA was significantly associated with prolonged TBUT (mean difference [MD] = 1.95 s, 95% confidence interval [CI]: 1.38 to 2.53, P < 0.001), improved Schirmer's test scores without anesthesia (MD = 2.14 mm, 95%CI: 0.68 to 3.59, P = 0.004), and reduced corneal fluorescein staining (standardized MD = - 1.62, 95%CI: - 3.16 to - 0.08, P = 0.039). However, CsA did not significantly improve Schirmer's test scores with anesthesia (MD = 1.73 mm, 95%CI: - 0.11 to 3.56 to 2.79, P = 0.066) or OSDI scores (MD = - 2.73, 95%CI: - 7.42 to 1.97, P = 0.255) compared to control. All treatment-related adverse events were mild.
Conclusion: Topical CsA significantly improves ocular surface and tear film parameters following cataract surgery and may be considered for the postoperative management of ocular surface disturbance and dry eye. However, considering the very low to moderate certainty of evidence, further high-quality RCTs are needed to validate for these findings.
期刊介绍:
International Ophthalmology provides the clinician with articles on all the relevant subspecialties of ophthalmology, with a broad international scope. The emphasis is on presentation of the latest clinical research in the field. In addition, the journal includes regular sections devoted to new developments in technologies, products, and techniques.